neuropeptide Y receptor Y1Genealiases: NPY1-R · NPYR
Q-omics provides the consensus-scored NPY1R profile across patient tissues and cancer cell-line models. NPY1R expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NPY1R is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NPY1R RNA expression shows 15,209 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRC, and THYM as cancer lineages where NPY1R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPY1R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPY1R survival associations across molecular data types. NPY1R RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPY1R RNA expression–survival associations across cancer types. High NPY1R expression shows unfavorable associations in CESC, but favorable associations in BRCA, MESO, LIHC, KIRC and ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for NPY1R RNA expression.
This table summarizes NPY1R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NPY1R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPY1R shows lower tumor expression in KIRC, COAD, KICH, KIRP, LIHC and HNSC. The KIRC box plot shows higher NPY1R RNA expression in normal versus tumor tissue (log2 FC = −1.917, t-test p < 0.001).
This table shows molecular features associated with NPY1R in patient tissues and cancer cell lines. In patient samples, NPY1R shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPY1R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
